Please login to the form below

Not currently logged in
Email:
Password:

Afrezza

This page shows the latest Afrezza news and features for those working in and with pharma, biotech and healthcare.

Sanofi abandons inhaled insulin pact with Mannkind

Sanofi abandons inhaled insulin pact with Mannkind

Sanofi abandons inhaled insulin pact with Mannkind. Poor sales prompt return of Afrezza rights less than a year after its launch. ... Sanofi has handed back rights to inhaled insulin drug Afrezza to Mannkind, less than a year after its launch, after the

Latest news

  • AstraZeneca and its diabetes plans AstraZeneca and its diabetes plans

    A good example of this is MannKind and Sanofi's Afrezza (insulin human), the world's first inhaled that made it to market.

  • Sanofi's CEO search ends as Bayer's Brandicourt takes the job Sanofi's CEO search ends as Bayer's Brandicourt takes the job

    Afrezza. The biggest of these products could well be alirocumab, one of the leaders in the new PCSK9 class of cholesterol-lowering drugs that have been tipped to make multibillion dollars

  • Sanofi launches inhaled insulin in US Sanofi launches inhaled insulin in US

    The device Afrezza will be distributed in. Sanofi has launched what will be the only inhaled insulin available to treat people with diabetes in the US. ... Afrezza is the only product of its kind available in the US and offers patients an alternative to

  • Sanofi plans 18 new product launches by 2020 Sanofi plans 18 new product launches by 2020

    These include long-acting Lantus follow-up Toujeo (insulin glargine), rapid-acting insulin Afrezza and Lixilan, a combination of insulin glargine and recently-introduced GLP-1 agonist Lyxumia (lixisenatide.

  • Sanofi cuts $925m deal for MannKind's inhaled insulin Sanofi cuts $925m deal for MannKind's inhaled insulin

    Sanofi cuts $925m deal for MannKind's inhaled insulin. French company bolsters diabetes business with Afrezza collaboration. ... This inhaler is designed to be used with Mannkind's inhaled insulin Afrezza.

More from news
Approximately 7 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2016 Deal Watch January 2016

    It was a big news month for Sanofi, also in the news for terminating its licensing deal with MannKind for Afrezza (inhaled insulin). ... The original deal was a worldwide exclusive licence for the commercialisation of Afrezza in diabetes, with expected

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    The only alternative to injections of the hormone at the moment is Mannkind's inhaled insulin Afrezza - partnered with Sanofi - which has not gained much momentum yet in the marketplace with

  • Going the distance Going the distance

    The first of these came in February with the debut of Afrezza, the only inhaled insulin available in the US. ... Following hot on the heels of Afrezza has been Toujeo (insulin glargine), the new basal insulin that will be crucial to moving away from

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    8, 300. MannKind/ Sanofi. Licence. Afrezza (human insulin) Rapid-Acting Inhaled Insulin (approved US).

  • Pharma deals during August 2014 Pharma deals during August 2014

    Having said that nerves must still be twitching given the relatively modest $150m upfront payment and MannKind's 10-year struggle to get Afrezza to this point. ... The deal, a global licence to develop and market Afrezza, comes less than seven weeks

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics